Substance / Medication

Lutetium (177-Lu) dotatate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Exosomal RNA biomarkers in pancreatic ductal adenocarcinoma: Systematic review and meta-analysis.
Tiyuri Amir, Hatami Haniyeh, Mobarezi Zahra et al. · Clin Chim Acta · 2026
PMID: 40780456Meta-Analysis
Association of Pancreatic Cancer with Acute Pancreatitis: A Systematic Review and Meta-Analysis.
Lee Jimin, Creanga-Marariu Ioana, Németh Jázmin et al. · Clin Transl Gastroenterol · 2026
PMID: 41066080Meta-AnalysisFull text (PMC)
Simple mucinous cysts of the pancreas: Clinical and imaging findings - Case series and systematic review of the literature.
De Robertis Riccardo, Cardobi Nicolò, Luchini Claudio et al. · Eur J Radiol · 2026
PMID: 41192204Meta-Analysis
Systematic review and meta-analysis of the efficacy and safety of [Lu]Lu-edotreotide ([Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.
Baum Richard P, Fricke Julia G, Ruhwedel Tristan et al. · J Neuroendocrinol · 2026
PMID: 41204752Meta-AnalysisFull text (PMC)
Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
Chan Dennis S, Kanagaratnam Aran L, Pavlakis Nick et al. · J Neuroendocrinol · 2025
PMID: 37987535Meta-AnalysisFull text (PMC)
Endoscopic Ultrasound-Guided Fine Needle Acquisition for Evaluation of Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Ye Xiaohua, Hua Hongjun, Hu Chunxiao et al. · J Clin Gastroenterol · 2025
PMID: 39312536Meta-Analysis
Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms.
La Salvia Anna, Modica Roberta, Spada Francesca et al. · Endocrine · 2025
PMID: 39671148Meta-Analysis
Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Séguier Denis, Parent Pauline, Duterque-Coquillaud Martine et al. · Eur Urol Oncol · 2025
PMID: 39824723Meta-Analysis
Primary hepatic neuroendocrine neoplasms of children, a systematic review.
Samady Khanghah Ali, Madadi-Sanjani Omid, Abdolzadeh Anahita et al. · J Neuroendocrinol · 2025
PMID: 39924853Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lutetium (177-Lu) dotatate (substance)
SNOMED CT
781259000
UMLS CUI
C3272344

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.